利西布与尼沃卢马布联合使用的安全性和有效性:一项针对高级固体瘤患者的Ib期研究
Benedito A Carneiro1, Robert M Jotte2,3, Nashat Y Gabrail4
1Legorreta Cancer Center at Brown University, Lifespan Cancer Institute, Providence, Rhode Island.
科潘利西布和尼沃卢马布的组合在先进的固体瘤中显示出抗瘤作用. 这种新的策略可能通过调节瘤免疫力来提高免疫检查点抑制剂的有效性.
科学领域:
- 在瘤学瘤学.
- 免疫治疗是一种免疫疗法.
- 药理学 药理学是指药理学的学科.
背景情况:
- 临床前模型表明,可潘利西布和免疫检查点抑制剂之间存在协同作用.
- 这项研究调查了在先进的固体瘤中使用copanlisib和nivolumab的组合.
研究的目的:
- 确定推的二期Copanlisib加Nivolumab的剂量.
- 评估组合治疗的安全性,耐受性和有效性.
- 探索治疗反应的潜在预测生物标志物.
主要方法:
- 阶段Ib,非随机化,开放标签,剂量升级研究.
- 患者接受了尼沃卢马布加上升级剂量的可潘利西布 (45毫克或60毫克).
- 进行了安全性,疗效和生物标志物分析.
主要成果:
- 60毫克的可潘利西布加上240毫克的尼沃卢马布被确定为推的II期剂量.
- 这种组合通常耐受良好,并有可管理的不良事件.
- 在18.8%的患者中观察到部分反应,表明抗瘤活性.
结论:
- 利西布和尼沃卢马布的组合显示出抗瘤作用,并且耐受性良好.
- 科帕尼西布调节生物标志物,表明免疫调节作用可能会增强检查点抑制剂的疗效.
- 对于这种新的组合策略,需要进一步调查.
更多相关视频
10:18Author Spotlight: Magnetic Fluorescent Bead-Based Dual-Reporter Flow Analysis of PDL1-Vaxx Peptide Vaccine-Induced Antibody Blockade of the PD-1/PD-L1 Interaction
Published on: July 7, 2023
15:04Potentiation of Anticancer Antibody Efficacy by Antineoplastic Drugs: Detection of Antibody-drug Synergism Using the Combination Index Equation
Published on: January 19, 2019
相关概念视频
Targeted Cancer Therapies
There are several types of targeted therapies against...
Treatment Resistant Cancers
Combination Therapies and Personalized Medicine
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
Chemotherapy-Induced Nausea and Vomiting: Neurokinin-1 Receptor Antagonists
Chemotherapy-Induced Nausea and Vomiting: Cannabinoids
Two synthetic agonists of THC,...
Cancer Therapies
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
